
Rockwell Medical RMTI
$ 1.22
27.44%
Quarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Long Term Debt Current 2011-2026 | RMTI
Annual Long Term Debt Current Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 M | 1.48 M | 7.38 M | - | 1.49 M | - | - | - | - | - | 2.31 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.38 M | 1.38 M | 2.81 M |
Long Term Debt Current of other stocks in the Drug manufacturers industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
5.36 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.14 | -4.62 % | $ 123 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
357 K | $ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
3.91 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
13.4 K | - | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
1.38 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
1.72 M | $ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
806 K | $ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
39.3 K | $ 1.25 | - | $ 21.8 M | ||
|
Jupiter Wellness
JUPW
|
213 K | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.62 | 0.62 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
61 M | $ 6.75 | -3.3 % | $ 2.46 B | ||
|
Neoleukin Therapeutics
NLTX
|
2.56 M | - | - | $ 193 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
34.3 M | $ 1.58 | -2.17 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
4.27 M | $ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | $ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
27.8 M | $ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 3.33 | 1.06 % | $ 4.13 M | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
928 K | $ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
2.47 M | $ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
1.79 M | $ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
340 K | $ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
1.07 M | $ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
1.47 M | $ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
80.6 M | $ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
916 K | - | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
98.7 K | $ 0.83 | -9.94 % | $ 3.58 M |